The Impact of Zinc and Probiotics in Preventing Pediatric Antibiotic-Associated Diarrhea in Southern Iran
NCT ID: NCT06665503
Last Updated: 2024-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
165 participants
INTERVENTIONAL
2020-09-01
2021-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Zinc Supplementation and Severe and Recurrent Diarrhea
NCT01306097
A Comprehensive Analysis of the Comparative Efficacy of Multimodal Diarrhea Therapies in the Paediatric Population
NCT06588036
Comparing the Efficacy of Different Zinc Formulations in the Treatment of Diarrhea
NCT00682955
Efficacy Of Probiotics vs. Zinc vs. Probiotics-Zinc Combination On Acute Diarrhea In Children
NCT03684538
Efficacy of Zinc Sulfate With Probiotics for the Treatment of Acute Diarrhea in Children
NCT01140074
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
65 children in cotrol group
Only standard medication.
No interventions assigned to this group
65 children in Zinc group
The zinc group received oral zinc supplementation; 2.5 ml every 12 hours for children aged \<1 year and 5 ml every 12 hours for older children.
Zinc Supplement, probiotic
received oral zinc supplementation; 2.5 ml every 12 hours for children aged \<1 year and 5 ml every 12 hours for older children; the probiotics group received oral probiotics; 1 probiotic sachet
65 children in Probiotic group
The probiotics group received oral probiotics; 1 probiotic sachet (KidiLact: Lacticaseibacillus rhamnosus, Lactobacillus reuteri, Lactobacillus acidophilus, Bifidobacterium infantis, Lactobacillus acidophilus, Bifidobacterium bifidum and Streptococcus thermophilus)
Zinc Supplement, probiotic
received oral zinc supplementation; 2.5 ml every 12 hours for children aged \<1 year and 5 ml every 12 hours for older children; the probiotics group received oral probiotics; 1 probiotic sachet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zinc Supplement, probiotic
received oral zinc supplementation; 2.5 ml every 12 hours for children aged \<1 year and 5 ml every 12 hours for older children; the probiotics group received oral probiotics; 1 probiotic sachet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. prescribed antibiotics for various medical conditions
Exclusion Criteria
2. Underlying chronic disease
3 Months
3 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hormozgan University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohammad Bagher Rahmati
Hormozgan University of Medical Sciences
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MohammadBagher Rahmati, Pediatrician
Role: STUDY_DIRECTOR
Hormozgan University of Medical Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hormozgan University of Medical Sciences
Bandar Abbas, Hormozgan, Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Hormozgan University
Identifier Type: OTHER
Identifier Source: secondary_id
IR.HUMS.REC.1399.579
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.